Treatment of disease with antibodies against high molecular weight kininogen domain 5

US7332161B2 · kind B2 · utility

Assignees

• Temple University-Of The Commonwealth System of Higher Education · US
• Bristol-Myers Squibb Pharma Company · US

Inventors

• Robert W. Colman · Moylan, US
• Shaker A. Mousa · McKeesport, US

Key dates

• Filing date: Jan 30, 2006
• Grant date: Feb 19, 2008
• Expiry date: Jan 30, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.